Uses of Firizin: - Tuberculosis (TB) Tuberculosis Hypersensitivity; existing liver disease; acute gout or hyperuricaemia. Porphyria. Pregnancy and lactation.

How to use Pyrazinamide: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Pyrazinamide may be taken with or without food, but it is better to take it at a fixed time. Administration: Should be taken with food. Adult Dose: Oral Tuberculosis Adult: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: <50 kg: 1.5 g daily; >50 kg: 2 g daily. For intermittent supervised 2-mth treatment: <50 kg: 2 g 3 times wkly; >50 kg: 2.5 g 3 times wkly. Hepatic impairment: Severe: Contraindicated. Child Dose: Oral Tuberculosis Child: As part of a multidrug regimen: For standard unsupervised 2-mth treatment: 35 mg/kg daily. For intermittent supervised 2-mth treatment: 50 mg/kg 3 times wkly. Renal Dose: Renal impairment: May need dose reduction.

Antagonises the effect of uricosuric agents (e.g. probenecid, sulfinpyrazone). May reduce the contraceptive effect of oestrogens. May inactivate oral typhoid vaccine. May increase the serum concentration of ciclosporin. May enhance the hepatotoxic effect of rifampicin.

Hypersensitivity; existing liver disease; acute gout or hyperuricaemia. Porphyria. Pregnancy and lactation.

Common - Jaundice - Hepatitis (viral infection of liver) - Increased liver enzymes - Joint pain 1-10% Malaise,Nausea,Vomiting,Anorexia,Arthralgia,Myalgia <1% Fever,Rash,Itching,Acne,Photosensitivity,Gout,Dysuria,Porphyria,Thrombocytopenia,Hepatotoxicity,Interstitial nephritis Potentially Fatal: Severe liver damage, fulminant hepatitis.

Precaution: Patient w/ DM, history of gout. Mild to moderate hepatic and renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor liver function, serum uric acid, sputum culture; chest x-ray 2-3 mth into treatment and at completion.

Overdosage experience is limited. In one case report of overdose, abnormal liver function tests developed. These spontaneously reverted to normal when the drug was stopped. Clinical monitoring and supportive therapy should be employed. Pyrazinamide is dialyzable.

Store between 15-30° C.

Anti-Tubercular Chemotherapeutics

Pyrazinamide may be bacteriostatic or bactericidal in action, depending on the concentration of the drug attained at the site of the infection and the susceptibility of the infecting organism. Its activity appears to partly depend on conversion of the drug to pyrazinoic acid (POA), which lowers the pH of the environment below that which is necessary for growth of Mycobacterium tuberculosis. Susceptible strains of M. tuberculosis produce pyrazinamidase, an enzyme that deaminates pyrazinamide to POA, and the in vitro susceptibility of a given strain of the organism appears to correspond to its pyrazinamidase activity.

Pregnancy Category C. Animal reproduction studies have not been conducted with Pyrazinamide. It is also not known whether Pyrazinamide can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Pyrazinamide should be given to a pregnant woman only if clearly needed.Nursing Mothers: Pyrazinamide has been found in small amounts in breast milk. Therefore, it is advised that Pyrazinamide be used with caution in nursing mothers taking into account the risk-benefit of this therapy.